ImmunoGen develops targeted anticancer therapeutics. The company s proprietary Tumor-Activated Prodrug technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. The company uses its technology to develop product candidates. In addition, it licenses the technology to other drug development companies. Companies that have licensed ImmunoGen s technology include Genetech; the Centocor division of Johnson & Johnson; Biogen Idec; sanofi-aventis Group; Boehringer Ingelheim; Milennium Pharmaceuticals; and Abgenix. ImmunoGen is headquartered in Cambridge, Mass., and has a manufacturing facility in Norwood, Mass. The company has more than 170 employees engaged in research and development, clinical research, manufacturing and administrative functions.